Maintenance Therapy for Advanced Non-small Cell Lung Cancer: Current Status, Controversies, and Emerging Consensus
Open Access
- 28 April 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 16 (9) , 2496-2504
- https://doi.org/10.1158/1078-0432.ccr-09-2328
Abstract
Maintenance therapy refers to the use of an active therapeutic agent for extended duration following frontline induction therapy for patients with advanced stage non-small cell lung cancer (NSCLC). Multiple clinical trials reported within the last few months have shown a beneficial role for maintenance therapy especially in select patient groups characterized by histology and/or molecular profile. With the recent approval by the U.S. Food and Drug Administration and European Medicines Agency of pemetrexed for maintenance therapy, a new treatment paradigm has been introduced to the treatment of NSCLC. This article reviews recent data with maintenance therapy in advanced NSCLC and discusses the implications for routine patient care and future drug development. Clin Cancer Res; 16(9); 2496–504. ©2010 AACR.Keywords
This publication has 26 references indexed in Scilit:
- Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 StudyJournal of Clinical Oncology, 2009
- The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III StudiesThe Oncologist, 2009
- Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2007
- Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the LiteratureThe Oncologist, 2007
- The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR AgentsMolecular Cancer Research, 2007
- Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trialBlood, 2006
- Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancerBritish Journal of Cancer, 2006
- Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2005
- Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective studyCancer, 1989